Precision Medicine in Cancer Therapy

1. Front Matter

   Pages i-x

   PDF

2. Individual Types of Cancer Precision Medicine

   1. Front Matter

      Pages 1-1

      PDF

   2. Targeted Therapies in Non-small-Cell Lung Cancer

      • Addie Hill, Rohan Gupta, Dan Zhao, Ritika Vankina, Idoroenyi Amanam, Ravi Salgia

      Pages 3-43

   3. Update on Precision Medicine in Breast Cancer

      • Jasgit C. Sachdev, Ana C. Sandoval, Mohammad Jahanzeb

      Pages 45-80

   4. The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers

      • Michael J. Demeure

      Pages 81-108

3. Currently Available Techniques

   1. Front Matter

      Pages 109-109

      PDF

   2. Immunohistochemistry-Enabled Precision Medicine

      • Zoran Gatalica, Rebecca Feldman, Semir Vranić, David Spetzler

      Pages 111-135

   3. Genomics-Enabled Precision Medicine for Cancer

      • Alison Roos, Sara A. Byron

      Pages 137-169

   4. Utilization of Proteomic Technologies for Precision Oncology Applications

      • Mariaelena Pierobon, Julie Wulfkuhle, Lance A. Liotta, Emanuel F. Petricoin III

      Pages 171-187

   5. Precision Medicine-Enabled Cancer Immunotherapy

      • John K. Lee, Saul J. Priceman

      Pages 189-205

4. Future Precision Medicine

   1. Front Matter

      Pages 207-207

      PDF

   2. Use of Precision Imaging in the Evaluation of Pancreas Cancer

      • Ronald L. Korn, Syed Rahmanuddin, Erkut Borazanci

      Pages 209-236

   3. Single-Cell Sequencing in Precision Medicine

      • Julia E. Wiedmeier, Pawan Noel, Wei Lin, Daniel D. Von Hoff, Haiyong Han

      Pages 237-252

   4. Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients

      • Stephen Gately

      Pages 253-264

   5. Artificial Intelligence and Personalized Medicine

      • Nicholas J. Schork

      Pages 265-283

This book presents the latest advances in precision medicine in some of the most common cancer types, including hematological, lung and breast malignancies. It also discusses emerging technologies that are making a significant impact on precision medicine in cancer therapy. In addition to describing specific approaches that have already entered clinical practice, the book explores new concepts and tools that are being developed.


Precision medicine aims to deliver personalized healthcare tailored to a patient’s genetics, lifestyle and environment, and cancer therapy is one of the areas in which it has flourished in recent years. Documenting the latest advances, this book is of interest to physicians and clinical fellows in the front line of the war on cancer, as well as to basic scientists working in the fields of cancer biology, drug development, biomarker discovery, and biomedical engineering. The contributing authors include translational physicians withfirst-hand experience in precision patient care.

• Genomics enabled precision medicine
• Proteomics enabled precision medicine
• Metabolomics enabled precision medicine
• Imaging precision medicine
• Single cess sequencing in precsion medicine
• Microbiome in precision medicine
• Perspectives on precision medicine
• Biomedical Engineering
• Biomarker Discovery
• Emerging Technologies
• New tools in precision medicine
• Drug development

• Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, USA

  Daniel D. Von Hoff, Haiyong Han

Daniel Von Hoff is a physician scientist whose major interest is the development of new anticancer agents, in both clinic and laboratory settings. He played a pivotal role in the development of many of the anticancer agents now being used routinely. He also pioneered the application of genomics profiling in the clinical care of patients with cancer. Dr. Von Hoff is a former member of the FDA’s Oncology Drug Advisory Committee (ODAC) and served on President Bush’s National Cancer Advisory Board. He is a former president of the American Association of Cancer Research (AACR) and a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO).


Haiyong Han is a tumor biologist with a major interest in targeted drug discovery.  He has more than 20 years of experience in preclinical drug development for cancers, particularly pancreatic cancer. His major areas of expertise include the identification and validation of drug targets and biomarkers, lead identification and optimization, and preclinical evaluation and development. Dr. Han has published more than 70 peer reviewed articles and was an inventor on 15 patents/patent applications.

Policies and ethics